Trial Profile
Comparison of efficacy and safety of 5-day and 10-day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Dec 2017 Results assessing the Predictors of Response and Survival in AML patients Treated with Guadecitabine (n=206) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results reporting long tem survival and composite complete response (CRc) rate data in various prognostic subgroups in the overall relapsed/refractory acute myeloid leukemia patient population treated with guadecitabine, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 24 Sep 2015 New trial record